HA22 is licensed to Medimmune and been given the name Moxetumomab pasudotox (Moxe). It has been tested in patients with advanced chemo-resistant hairy cell leukemia (HCL) in adults and in acute lymphoblastic leukemia in children. The HCL phase 3 trial has met its FDA mandated efficacy endpoint and the agent may be approved by the FDA this year. New trials with Moxe are planned in patients with less advanced Hairy Cell Leukemia in combination with an immune suppressing agent. LMB-100 is an immunotoxin targeting mesothelin expressing cancers. In collaboration with Drs Hassan and Alewine, it is being tested in patients with mesothelioma and pancreatic cancer as a single agent and in combination with Abraxane. Finally, because the development of anti-drug antibodies to agents like LMB-100, interferes with the activity of immunotoxins in humans, we have collaborated with Selecta Biosciences and shown that ADA formation vs immunotoxins is prevented and immune tolerance induced by co-administration nanoparticles containing rapamycin. A clinical trial combining these 2 agents has recently opened.
| Chandramohan, Vidyalakshmi; Pegram, Charles N; Piao, Hailan et al. (2017) Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. Appl Microbiol Biotechnol 101:2747-2766 |
| Hassan, Raffit; Alewine, Christine; Pastan, Ira (2016) New Life for Immunotoxin Cancer Therapy. Clin Cancer Res 22:1055-8 |
| Hassan, Raffit; Thomas, Anish; Alewine, Christine et al. (2016) Mesothelin Immunotherapy for Cancer: Ready for Prime Time? J Clin Oncol 34:4171-4179 |
| Bao, Xuhui; Pastan, Ira; Bigner, Darell D et al. (2016) EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. Receptors Clin Investig 3: |
| Pastan, Ira; Hassan, Raffit (2014) Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74:2907-12 |
| Sharon, Elad; Zhang, Jingli; Hollevoet, Kevin et al. (2012) Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med 50:721-5 |
| Kelly, Ronan J; Sharon, Elad; Pastan, Ira et al. (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11:517-25 |
| Kreitman, Robert J; Tallman, Martin S; Robak, Tadeusz et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822-8 |
| Mehta, Ankit I; Choi, Bryan D; Ajay, Divya et al. (2012) Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol 9:305-10 |
| Mehta, Ankit I; Choi, Bryan D; Raghavan, Raghu et al. (2011) Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel) 3:201-6 |
Showing the most recent 10 out of 21 publications
